Investors in Assembly Biosciences (NASDAQ:ASMB) Have Unfortunately Lost 90% Over the Last Five Years
Assembly Biosciences Reports Key Preclinical Data From ABI-5366, And First Data From ABI-1179
Express News | Assembly Biosciences To Present Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data
Insiders Buying American Software And 2 Other Stocks
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the
Assembly Biosciences(ASMB.US) 10% Shareholder Buys US$111.63K in Common Stock
$Assembly Biosciences(ASMB.US)$ 10% Shareholder Schornstein Alexander purchased 9,000 shares of common stock on Jul 3, 5, 2024 at an average price of $12.4 for a total value of $111.63K. So
ASSEMBLY HIRES SHIVAPRASAD NAIR AS MANAGING DIRECTOR OF NEW GLOBAL DELIVERY OFFERING
The Stagwell (STGW) media agency expands global footprint and strengthens operations in India, Egypt, and the Philippines BANGALORE, India, July 3, 2024 /PRNewswire/ -- Global omnichannel media agenc
Express News | Assembly Biosciences Doses First Participant In Phase 1b Trial Of ABI-4334, A Next-Gen Capsid Assembly Modulator For Chronic Hepatitis B Treatment
Express News | Assembly Biosciences Doses First Participant in Phase 1B Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate Abi-4334 for the Treatment of Chronic Hepatitis B Virus Infection
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 –SOUTH SAN FRANCISC
Express News | Assembly Biosciences: Funding Supports Advancement of Antiviral Portfolio, and Extends Cash Runway Into Q1 2026
Assembly Biosciences: Portfolio Includes Four Candidates in Clinical Development >ASMB
Assembly Biosciences: Portfolio Includes Four Candidates in Clinical Development >ASMB
Assembly Biosciences Announces $12.6 Million in Equity Financings
— Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runway into Q1 2026 —— Anticipated near term interim data read outs include A
Express News | HC Wainwright & Co. Reiterates Neutral on Assembly Biosciences
H.C. Wainwright Maintains Assembly Biosciences(ASMB.US) With Hold Rating
H.C. Wainwright analyst Ed Arce maintains $Assembly Biosciences(ASMB.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 40.0% and a total average return of 8.9% over
Assembly Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/13/2024 — HC Wainwright & Co. Reiterates → Neutral 04/01/2024 — HC Wainwright & Co. Reiterates → Neut
Express News | Assembly Biosciences Inc: Interim Data From Phase 1a Study Expected in Q3 2024
Express News | Assembly Biosciences Doses First Participant in Phase 1a/B Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate Abi-5366
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –– Phase 1b study portion of multiple ascendin
Express News | Assembly Biosciences To Present At EASL Congress 2024 Jun. 5-8